Predictive Biomarker for Endoscopic Therapy in Chronic Pancreatitis

Eligibility Criteria

• * adults older than 18 years;
• * Cambridge III or IV criteria for CP; or M-ANNHEIM criteria for definitive chronic pancreatitis;
• * scheduled for endoscopic therapy for ductal obstruction (may include lithotripsy, pancreatic duct dilation, or stone extraction to facilitate successful stenting) as part of routine clinical care based on multidisciplinary review;
• * pain present for ≥ 3 days per week for ≥ 3 months;
• * average pain over the last week ≥ 4 on a 11-point numeric rating scale (NRS).
• * chronic pain syndrome other than CP;
• * episode of acute pancreatitis within 2 months of enrollment;
• * endoscopic therapy including ERCP, EUS Guided Celiac Plexus Block or pancreatic surgery \< 6 months prior to enrollment;
• * active illicit drug use (excludes marijuana use);
• * American Society of Anesthesiologists classification \> 3;
• * immune-mediated pancreatitis or associated pancreatic neoplasms
• * Major neurological disease such as stroke, uncontrolled epilepsy, dementia
• * Diagnosis of schizophrenia
• * Chronic benzodiazepine use. Use of short acting benzodiazepine on as needed basis is acceptable if participant is able to hold benzodiazepine prior to EEG recording.
• * Pregnancy